Bli medlem
Bli medlem

Du är här


DanCann Pharma A/S: Strong Support from the DanCann Pharma Board of Directors, who convert their warrants into shares and buy more than 80,000 shares equaling DKK +400,000

COPENHAGEN, Denmark, 17 January 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has received great support from the Board of Directors in the latest transaction, where the Board of Directors has bought shares for more than DKK +400,000 in DanCann Pharma, equal more than +80,000 shares.

The members of the Board of Directors of DanCann Pharma have decided to convert their warrants into shares in the Company. Chairman of the Board Carsten Trads, Per Wester, Magnus Østergaard Dahlmann and Christian Carlsen have all chosen to express their great confidence in DanCann Pharma by exercising their right to convert their warrants and thereby invest further in the ambitious Company.

Chairman of the Board, Carsten Trads, comments on the transaction:

I am convinced that DanCann Pharma is facing a bright future. The Company has reached a great number of milestones in a short time, but we have only just begun. In the Board of Directors, we have high expectations for 2022, where we look forward to getting our EU-GMP approvals in place and further strengthening our production facilities. We would very much like to support this - also financially.


Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

This disclosure contains information that DanCann Pharma A/S is obliged to publish in accordance with the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 20 October 2021.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit:

For further information, please contact:

Jeppe Krog Rasmussen, CEO

Författare Cision